AIM: To investigate the feasibility of dose escalation using rapid arc (RA) and Helical Tomotherapy (HT) for patients with upper, middle and distal esophageal carcinomas, even for large tumor volumes. BACKGROUND: In esophageal cancer, for patients with exclusive radio-chemotherapy, local disease control remains poor. Planning study with dose escalation was done for two sophisticated modulated radiotherapy techniques: Rapid arc against Tomotherapy. MATERIALS AND METHODS: Six patients treated with a RA simultaneous integrated boost (SIB) of 60 Gy were re-planned for RA and HT techniques with a SIB dose escalated to 70 Gy. Dose volume histogram statistics, conformity indices and homogeneity indices were analyzed. For a given set of normal tissue constraints, the capability of each treatment modality to increase the GTV dose to 70 Gy was investigated. RESULTS: Either HT or VMAT may be used to escalate the dose delivered in esophageal tumors while maintaining the spinal cord, lung and heart doses within tolerance. Adequate target coverage was achieved by both techniques. Typically, HT achieved better lung sparing and PTV coverage than did RA. CONCLUSIONS: Dose escalation for esophageal cancer becomes clinically feasible with the use of RA and HT. This promising result could be explored in a carefully controlled clinical study which considered normal tissue complications and tumor control as endpoints.
AIM: To investigate the feasibility of dose escalation using rapid arc (RA) and Helical Tomotherapy (HT) for patients with upper, middle and distal esophageal carcinomas, even for large tumor volumes. BACKGROUND: In esophageal cancer, for patients with exclusive radio-chemotherapy, local disease control remains poor. Planning study with dose escalation was done for two sophisticated modulated radiotherapy techniques: Rapid arc against Tomotherapy. MATERIALS AND METHODS: Six patients treated with a RA simultaneous integrated boost (SIB) of 60 Gy were re-planned for RA and HT techniques with a SIB dose escalated to 70 Gy. Dose volume histogram statistics, conformity indices and homogeneity indices were analyzed. For a given set of normal tissue constraints, the capability of each treatment modality to increase the GTV dose to 70 Gy was investigated. RESULTS: Either HT or VMAT may be used to escalate the dose delivered in esophageal tumors while maintaining the spinal cord, lung and heart doses within tolerance. Adequate target coverage was achieved by both techniques. Typically, HT achieved better lung sparing and PTV coverage than did RA. CONCLUSIONS: Dose escalation for esophageal cancer becomes clinically feasible with the use of RA and HT. This promising result could be explored in a carefully controlled clinical study which considered normal tissue complications and tumor control as endpoints.
Authors: Shu-lian Wang; Zhongxing Liao; Ara A Vaporciyan; Susan L Tucker; Helen Liu; Xiong Wei; Stephen Swisher; Jaffer A Ajani; James D Cox; Ritsuko Komaki Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-19 Impact factor: 7.038
Authors: Zhen Zhang; Zhongxing Liao; Jing Jin; Jaffer Ajani; Joe Y Chang; Melenda Jeter; Thomas Guerrero; Craig W Stevens; Stephen Swisher; Linus Ho; James Yao; Pamela Allen; James D Cox; Ritsuko Komaki Journal: Int J Radiat Oncol Biol Phys Date: 2005-03-01 Impact factor: 7.038
Authors: Milan Vošmik; Miroslav Hodek; David Buka; Petra Sýkorová; Jakub Grepl; Petr Paluska; Simona Paulíková; Igor Sirák Journal: Rep Pract Oncol Radiother Date: 2020-02-25